EMA-HTA Parallel Scientific Advice: Challenges and Opportunities
Ulrike Fuchs
Broschiertes Buch

EMA-HTA Parallel Scientific Advice: Challenges and Opportunities

Conducting an EMA-HTA Parallel Scientific Advice for a Development Product between Clinical Phase I and Phase III

Versandkostenfrei!
Versandfertig in 6-10 Tagen
27,99 €
inkl. MwSt.
PAYBACK Punkte
14 °P sammeln!
Compared to regulatory agencies - focusing on the benefit/risk assessment of a product, typically evaluated in the strictly controlled setting of randomized controlled trials with close attention to internal validity, safety, efficacy and manufacturing - HTA bodies have different remits and, therefore, additional evidence requirements. Criteria for reimbursement decisions vary across countries but can include unmet medical needs, the relative effectiveness and safety of the drug, drug price, budget impact and cost-effectiveness. Designing a study suitable for regulatory approval might not alwa...